

Adult CIRB - Late Phase Emphasis Meeting Agenda

November 21, 2024

I New Study - Initial Review

CCTG-BR38, Consolidative Use of Radiotherapy to Block (CURB2) Oligoprogression in Patients with Metastatic Non-Small-Cell Lung Cancer - A Randomized Phase 3 Trial (Version Date 10/11/24)

II Continuing Review

A021806, A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer (Version Date 07/02/24)

III Continuing Review

A151216, Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) (Version Date 09/01/23)

IV Continuing Review

NRG-GY018, A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer (Version Date 10/18/24)

V Continuing Review

EA5191, A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC (Version Date 11/08/24)

VI Continuing Review

EA6194, Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study (Version Date 10/30/24)

VII Continuing Review

EA8153, Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial (Version Date 09/17/21)

VIII Continuing Review

NRG-GY023, A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer who have Received Prior Bevacizumab (Version Date 05/23/24)

IX Continuing Review

NRG-GU007, Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (Version Date 05/24/22)

X Continuing Review

NRG-GY005, A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS) (Version Date 07/27/23)

XI Continuing Review

NRG-HN006, Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer (Version Date 05/16/24)

XII Continuing Review

RTOG-1112, Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma (Version Date 09/23/22)

XIII Continuing Review

S0777, A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (Version Date 08/12/24)

XIV Continuing Review

S1706, A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer (Version Date 07/26/23)

XV Continuing Review

S1918, A Phase II/III Randomized Study of R-miniCHOP with or without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Version Date 05/15/24)

XVI Continuing Review

S2015, Melanoma Margins Trial (MelMarT-II): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma (Version Date 12/22/21)

XVII Continuing Review

EA2192, APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation (Version Date 10/02/23)

XVIII Continuing Review

EA2201, A Phase II Study of Neoadjuvant Nivolumab plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma (Version Date 08/18/23)
